BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HekaBio K.K. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies HekaBio K.K.'s drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06189963-750@assetmemo.bio
DTSTAMP:20261121T010131Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Troculeucel: Phase 1/2 readout est. (NCT06189963)
DESCRIPTION:Troculeucel\, phase 1/2\, Alzheimer's Disease.\nStudy: Clinical
  Study of SNK01 in Participants With Moderate Alzheimer's Disease\nEstimat
 ed primary completion: March 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/troculeucel#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06189963
URL:https://assetmemo.bio/drug/troculeucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228078-750@assetmemo.bio
DTSTAMP:20261121T010131Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Troculeucel: Phase 2 readout est. (NCT07228078)
DESCRIPTION:Troculeucel\, phase 2\, Alzheimer's Disease.\nStudy: Open-Label
  Extension Protocol to SNK01-AD01 Study\nEstimated primary completion: Apr
 il 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/troculeucel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722
 8078
URL:https://assetmemo.bio/drug/troculeucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
